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The role of metastasectomy for recurrent disease in 
patients with adenoid cystic carcinoma (ACC) is not 
defined clearly yet. A 52-year-old woman found two 
hepatic metastatic nodules 3 years after the com-
pletion of treatment for primary ACC of the trachea. 
After confirming the absence of other lesions, meta-
stasectomy was performed on the two metastatic 
nodules. Regular follow-up for more than 24 months 
showed no evidence of recurrent disease after the 
hepatic metastasectomy. Therefore, we suggest meta-
stasectomy as an option for certain cases of meta-
static ACC. (Gut and Liver 2009;3:127-129)
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INTRODUCTION
  Adenoid cystic carcinomas (ACCs) are rare tumors, and 
mostly arise from salivary gland, especially minor salivary 
glands.
1 They can also arise in various sites of the head 
and neck including the tracheobronchial tree and even in 
sites outside the head and neck, such as breast, uterine 
cervix, prostate, and the skin.
2 They have “paradoxical” 
behaviors. They grow slowly but have relentless and pro-
gressive clinical course. They are usually feasible for sur-
gical treatment at presentation but recur inevitably even 
after many years after complete resection. They seldom 
metastasize to regional lymph node but often metastasize 
to distant sites such as lung and bone. Therefore, 5-year 
survival rates are high but 10- to 20-year survival rates 
are dismally low.
3 If metastasis occurs, watchful waiting, 
radiation therapy, palliative surgery, and systemic chemo-
therapy would be treatment options, but no standard pal-
liative treatment modalities are exist.
4 Despite the role of 
metastasectomy to control metastatic tumors in patients 
w i t h  d i f f e r e n t  p r i m a r y  t u m o r s  o f  A C C s  i s  u n c e r t a i n  a n d  
controversial, there are some series or anecdotal experi-
ences of promising results of metastasectomy of pulmo-
nary metastatic tumors or of hepatic metastatic tumors.
5-9 
We here present one case of metastasectomy of hepatic 
metastatic tumors of ACC of the trachea, in which the 
patient lives for more than 24 months without the evi-
dence of progressive disease or further recurrence.
CASE REPORT
  A 52-year-old woman came to Oncology Clinic to con-
sult treatment of hepatic metastatic tumors. She had un-
dergone laryngotrachectomy and thyoridectomy with me-
diastinal tracheostomy for ACC of the trachea followed by 
radiotherapy for residual tumors at surgical resection 
margin 3 years before the consultation. The pathology of 
the resected tumors, measuring 7×4×3 cm from the just 
below level of vocal cord to tracheal ring, had been re-
ported to be ACC with predominantly tubular histology, 
extending to subglottic laryngeal wall and thyroid gland 
without lymphovascular tumor emboli. The tumor cells 
had uniform round-to-angulated basophilic nuclei, and did 
not demonstate notable pleomorphism or mitotic activity. 
They formed tubular structures with microcysts in the cord, 
with surrounding hyalinized stroma (Fig. 1). Although she 
had to undergo the radiotherapy for residual tumors, no 
distant metastasis had been identified on whole body 
positron emission tomography (PET) and bone scan at 128   Gut and Liver, Vol. 3, No. 2, June 2009
Fig. 1. Pathology of the primary tumor. The tumor cells had uniform round-to-angulated basophilic nuclei, and did not demonstrate
notable pleomorphism or mitotic activity. They appeared as tubular structures with microcysts in the cord, with surrounding 
hyalinized stroma. The tumor showed a mixed (A) but predominantly tubular (B) pattern (A, H&E stain, ×40; B, H&E stain, 
×200).
Fig. 3. Whole PET scan. Two hypermetabolic lesions were 
present in the liver (solid arrow and arrowhead).
Fig. 2. CT scan of the upper abdomen. There were two masses 
in liver segments VII and VIII. Segment VIII contained a 
poorly enhanced, round, 3-cm mass, and segment VII con-
tained a peripherally enhanced, round, 4.5-cm cystic mass.
the time of the initial operation.   
  Her chest CT showed two nodules in the segment VII 
and VIII of liver (Fig. 2) while her abdomen/pelvis CT 
and whole body PET-CT showed no other metastatic le-
sions except the above two metastatic nodules (Fig. 3). 
Her performance status was good with ECOG perform-
ance status of 0 and her liver function test as well as oth-
er organ function tests was normal. She underwent the 
right lobectomy of the liver as metastasectomy. The final 
pathology confirmed that there were the two tumors only, 
measuring 5×4×4 cm in the segment VII and 3×3×2 cm 
in the segment VIII, respectively and there was no rem-
nant tumor. The pathology of hepatic tumors was the 
same to that of the prior tumor of the trachea. No lym-
phovascular invasion and perineural invasion was identi-
fied in the metastatic tumors as well (Fig. 4). To date, 
she has been followed up regularly without evidence of 
progressive disease or further recurrence for more than 
24 months. 
DISCUSSION
  The role of metastasectomy in ACCs is still debatable, 
but sometimes suggestive in a selected subset of patients. Park IK, et al: Metastasectomy in Adenoid Cystic Carcinoma of the Trachea   129
Fig. 4. Metastatic adenoid cystic carcinoma (ACC) in the liver. (A) Gross findings showing two lesions. (B) Microscopic findings 
showing a metastatic ACC (H&E stain, ×100).
Usually, metastasectomy is often undergone when all 
metastatic tumors are potentially completely resectable 
under the control of the primary site and patients have an 
adequate performance status and a good cardiopulmonary 
function. Of interest, low tumor burden or less than 6 
metastatic tumors and favorable disease-free interval of 
more than 3 years were sometimes suggested to be se-
lection criteria for pulmonary metastasectomy of ACC.
7 
The lack of systemic therapeutic alternatives is also sug-
gested one of important selection criteria. In the current 
case, she had disease-free interval of 3 years, potentially 
resectable 2 metastatic nodules, and good performance 
status and residual liver function as well as cardiopulmo-
nary function.
  Some argue that as tumor growth of metastatic tumors 
o f  A C C s  i s  s l o w ,  w a t c h f u l  w a i t i n g  c a n  b e  m o r e  a p p r o -
priate, especially when there are no or few symptoms. 
However, although metastatic tumors grow optimistically 
slowly, they have relentless and progressive disease 
course, and long-term outcomes are dismal. Whereas, the 
response rates for cytotoxic chemotherapy are extremely 
variable and inconsistent, and response duration was gen-
erally short.
10 In addition, disease stabilization is more of-
ten seen after cytotoxic chemotherapy than objective re-
sponse but it should be interpreted very cautiously be-
cause the ACC, as mentioned above, usually grow slowly. 
Therefore, systemic cytotoxic chemotherapy should be re-
served for those who have symptomatic and rapidly pro-
gressive disease. If recurrent or metastatic tumors are to-
tally resectable with conserving organ functions, meta-
stasectomy could be considered as one of the treatment 
options, such as cytotoxic chemotherapy or watchful wai-
ting.
  In conclusion, metastasectomy in patients with ACCs 
can be resorted to in a very highly selected subset of pa-
tients, who have potentially completely resectable meta-
static tumors under the control of primary tumors and 
adequate performance and organ functions.
REFERENCES
1. Bradley PJ. Adenoid cystic carcinoma of the head and neck: 
a review. Curr Opin Otolaryngol Head Neck Surg 2004; 
12:127-132.
2. Spiro RH, Huvos AG. Stage means more than grade in ad-
enoid cystic carcinoma. Am J Surg 1992;164:623-628.
3. Westra WH. The surgical pathology of salivary gland ne-
oplasms. Otolaryngol Clin North Am 1999;32:919-943.
4. Laurie SA, Licitra L. Systemic therapy in the palliative 
management of advanced salivary gland cancers. J Clin 
Oncol 2006;24:2673-2678.
5. Bobbio A, Copelli C, Ampollini L, et al. Lung metastasis 
resection of adenoid cystic carcinoma of salivary glands. 
Eur J Cardiothorac Surg 2008;33:790-793.
6. Liu D, Labow DM, Dang N, et al. Pulmonary meta-
stasectomy for head and neck cancers. Ann Surg Oncol 
1999;6:572-578.
7. Locati LD, Guzzo M, Bossi P, et al. Lung metastasectomy 
in adenoid cystic carcinoma (ACC) of salivary gland. Oral 
Oncol 2005;41:890-894.
8. Qureshi SS, Nadkarni MS, Shrikhande SV, et al. Hepatic 
resection for metastasis from adenoid cystic carcinoma of 
parotid gland. Indian J Gastroenterol 2005;24:29-30.
9. Zeidan BA, Hilal MA, Al-Gholmy M, El-Mahallawi H, 
Pearce NW, Primrose JN. Adenoid cystic carcinoma of the 
lacrimal gland metastasising to the liver: report of a case. 
World J Surg Oncol 2006;4:66.
10. Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcino-
ma: a review of chemotherapy and molecular therapies. 
Oral Oncol 2006;42;759-769.